These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3481457)

  • 1. Quinolone penetration into canine vaginal and urethral secretions.
    Gasser TC; Graversen PH; Larsen EH; Dørflinger T
    Scand J Urol Nephrol Suppl; 1987; 104():101-5. PubMed ID: 3481457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R; Griggs D; Andrews JM
    Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotics excretion in canine vaginal and urethral secretions.
    Hoyme U; Baumueller A; Madsen PO
    Invest Urol; 1978 Jul; 16(1):35-8. PubMed ID: 29017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fluoroquinolones].
    Baykal M; Akalin E
    Mikrobiyol Bul; 1987 Apr; 21(2):151-7. PubMed ID: 3482120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic drug monitoring of fluoroquinolone].
    Matsumoto F; Takahashi T; Morita M
    Nihon Rinsho; 1990 Feb; 48 Suppl():1217-22. PubMed ID: 2355524
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
    Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
    Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics of new quinolones.
    Lode H; Höffken G; Prinzing C; Glatzel P; Wiley R; Olschewski P; Sievers B; Reimnitz D; Borner K; Koeppe P
    Drugs; 1987; 34 Suppl 1():21-5. PubMed ID: 3481323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin and norfloxacin pharmacokinetics and prostatic fluid penetration in dogs after multiple oral dosing.
    Albarellos GA; Montoya L; Waxman S; Kreil V; Ambros LA; Hallu R; Rebuelto M
    Vet J; 2006 Sep; 172(2):334-9. PubMed ID: 15994101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Urinary tract infections: risk factors and therapeutic trends].
    Margariti PA; Astorri AL; Mastromarino C
    Recenti Prog Med; 1997 Feb; 88(2):65-8. PubMed ID: 9148368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosoxacin and cinoxacin distribution in prostate, vagina, and female urethra. An experimental study in dogs.
    Maigaard S; Frimodt-Möller N; Hoyme U; Madsen PO
    Invest Urol; 1979 Sep; 17(2):149-52. PubMed ID: 468515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental toxicity of fleroxacin and comparative pharmacokinetics of four fluoroquinolones in the cynomolgus macaque (Macaca fascicularis).
    Hummler H; Richter WF; Hendrickx AG
    Toxicol Appl Pharmacol; 1993 Sep; 122(1):34-45. PubMed ID: 8397453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the fluoroquinolone antibiotics.
    Just PM
    Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of enoxacin and norfloxacin in patients with cystitis.
    Yamamoto M; Nagai T; Takaba H; Hashimoto J; Miyake K
    Hinyokika Kiyo; 1987 Dec; 33(12):2141-4. PubMed ID: 3482344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The response of Streptococcus faecalis to ciprofloxacin, norfloxacin and enoxacin.
    Muranaka K; Greenwood D
    J Antimicrob Chemother; 1988 May; 21(5):545-54. PubMed ID: 3134318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway?
    Griffiths NM; Hirst BH; Simmons NL
    J Pharmacol Exp Ther; 1994 May; 269(2):496-502. PubMed ID: 8182517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the in vitro activity of enoxacin on bacterial strains recently isolated in a hospital milieu].
    Lembo M; Nani E; Covelli I; Amato G; Lavitola A
    G Batteriol Virol Immunol; 1985; 78(7-12):205-16. PubMed ID: 3870425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new fluoroquinolones: a review.
    Dabbs DJ; Limb DI; Spencer RC
    Med Lab Sci; 1987 Jan; 44(1):59-65. PubMed ID: 3309533
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro antibacterial activity of irloxacin (E-3432) on clinical isolates.
    Coll R; Esteve M; Moros M; Xicota MA; Parés J
    Drugs Exp Clin Res; 1987; 13(2):75-7. PubMed ID: 3582134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.